当前位置: 首页 > 期刊 > 《上海医药》 > 2022年第1期
编号:52335
耐药幽门螺杆菌感染治疗的研究进展
http://www.100md.com 2022年1月23日 2022年第1期
     张啸天 柯重伟

    摘 要 幽门螺杆菌是革兰阴性、微需氧的细菌,生存于胃部及十二指肠的各区域内,与消化性溃疡、胃癌、胃淋巴瘤等疾病密切相关。对幽门螺杆菌感染,临床上常采用抗生素治疗,但因细菌对抗生素耐药性问题越来越严重,治疗效果不理想。本文综述幽门螺杆菌感染治疗的最新研究进展,指出不同治疗方案在治疗幽门螺杆菌感染方面的作用。

    关键词 幽门螺杆菌 抗生素 耐药性

    中图分类号:R517.9; R453.2 文献标志码:A 文章编号:1006-1533(2022)01-0022-03

    Progress in the treatment of drug-resistant Helicobacter pylori infection

    ZHANG Xiaotian, KE Chongwei

    (Department of General Surgery, the Fifth People’s Hospital of Shanghai, Shanghai 200240, China)

    ABSTRACT Helicobacter pylori is a Gram-negative, micro-aerobic bacterium that lives in various regions of the stomach and duodenum and and is closely related to peptic ulcer, gastric cancer, gastric lymphoma and other diseases. Antibiotic therapy is often used in Helicobacter pylori infection, but the problem of antibiotic resistance is becoming more and more serious. This paper reviewed the latest research progress in the treatment of Helicobacter pylori infection, and pointed out the role of different treatments in the treatment of Helicobacter pylori infection.

    KEy wORDS Helicobacter pylori; antibiotics; drug-resistance ......

您现在查看是摘要页,全文长 10956 字符